Get started
Author

Alexey Smolin

Observed names: A Smolin, A V Smolin, A. Smolin, A. V. Smolin, A.V. Smolin, Alexei Smolin, Alexey V. Smolin, А.  V. Smolin
ORCID: 0000-0002-3023-0515
Observed ORCID: 0000-0002-3023-0515
OpenAlex ID: A5004445796
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
2019 · Barbara Burtness, Kevin J Harrington, et al. · The Lancet · 3,309
PDF
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,281
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 688
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
2020 · Naiyer A. Rizvi, Byoung Chul Cho, et al. · JAMA Oncology · 622
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
2019 · Cathy Eng, Tae Won Kim, et al. · The Lancet Oncology · 567
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
2020 · Thomas Powles, Michiel S van der Heijden, et al. · The Lancet Oncology · 501
PDF
Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC
2018 · N.A. Rizvi, B. Chul Cho, et al. · Annals of Oncology · 92
Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.
2019 · Solange Peters, Byoung Chul Cho, et al. · Cancer Research · 78
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide
2023 · Stephen V. Liu, Tony S.K. Mok, et al. · Lung Cancer · 50
PDF
Immunohistochemistry, Fluorescence in Situ Hybridization, and Reverse Transcription–Polymerase Chain Reaction for the Detection of Anaplastic Lymphoma Kinase Gene Rearrangements in Patients With Non–Small Cell Lung Cancer: Potential Advantages and Methodologic Pitfalls
2014 · Irina Demidova, Aleksei Barinov, et al. · Archives of Pathology & Laboratory Medicine · 35
Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide
2022 · Martin Reck, Tony S.K. Mok, et al. · Journal of Thoracic Oncology · 31
PDF
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy
2025 · Natasha B. Leighl, Luis Paz-Ares, et al. · Journal of Thoracic Oncology · 24
PDF
1781MO IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer
2020 · S.V. Liu, L. Horn, et al. · Annals of Oncology · 17
PDF
Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.
2019 · Naiyer A. Rizvi, Byoung Chul Cho, et al. · Journal of Clinical Oncology · 16
ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences
2022 · Irfan Cicin, Claudio Martin, et al. · Critical Reviews in Oncology/Hematology · 11
65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy
2023 · N. Leighl, L. Paz-Ares, et al. · Immuno-Oncology Technology · 10
PDF
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC
2019 · B.C. Cho, N. Reinmuth, et al. · Annals of Oncology · 10
KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.
2022 · Jacob Sands, Martin Reck, et al. · Journal of Clinical Oncology · 9
VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo)
2021 · S.V. Liu, T.S.K. Mok, et al. · Annals of Oncology · 7
PDF
IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care.
2023 · Martin Reck, Minu K Srivastava, et al. · Journal of Clinical Oncology · 6
PDF
OA11.06 IMpower133: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage Small-Cell Lung Cancer
2021 · M. Reck, L. Horn, et al. · Journal of Thoracic Oncology · 2
PDF
Analysis of prognostic factors for survival in the Russian population of patients with disseminated gastric cancer, who received ramucirumab as secondline therapy in the RAMSELGA trial
2020 · N. S. Besova, T. A. Titova, et al. · Meditsinskiy sovet = Medical Council · 2
PDF
Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia
2019 · N. S. Besova, T. A. Titova, et al. · Meditsinskiy sovet = Medical Council · 2
PDF
Ramucirumab in the treatment of refractory metastatic gastric cancer: Results from the RamSelGa trial
2019 · A. Tryakin, E. Perminova, et al. · Annals of Oncology · 2
Current issues of increasing the availability of innovative therapy for the treatment of patients with non-small cell lung cancer within the Russian healthcare system
2024 · K. K. Laktionov, S. K. Zyryanov, et al. · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · 1
PDF
Works count: 36
Citation count: 8,364
H-index: 14
I10-index: 17
Year
Topic
Type